American Journal of Clinical and Experimental Medicine

| Peer-Reviewed |

Multiple Sclerosis: Effect of Oral Administration of an Antioxidant Dietary Supplement in C57BL6/N Induced Model of Experimental Autoimmune Encephalomyelitis

Received: 26 March 2015    Accepted: 09 April 2015    Published: 18 April 2015
Views:       Downloads:

Share This Article

Abstract

In the pathogenesis of demyelinating diseases including multiple sclerosis (MS) an important role is played by oxidative stress. Increased energy requirements during remyelination of axons and mitochondria failure is one of the causes of axonal degeneration and disability in MS. In the presence of neurological diseases such as MS, F2-isoprostanes are concentrated in higher quantities. In this context, we analyzed the levels of F2-isoprostanes in the plasma and cerebrospinal fluid of mice of the strain C57BL6/N with an induced experimental autoimmune encephalomyelitis (EAE), orally treated with two concentrations of Citozym, a dietary supplement with evident antioxidant properties. Compared to the control group, Citozym-treated EAE-mouse had significantly lower levels of F2-isoprostanes both in plasma and in cerebrospinal fluid. Furthermore, according to the guidelines of IACUC, treatment with Citozym at higher concentrations drastically reduced neurological signs of induced EAE.

DOI 10.11648/j.ajcem.20150303.12
Published in American Journal of Clinical and Experimental Medicine (Volume 3, Issue 3, May 2015)
Page(s) 83-87
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Food Supplements, Antioxidants, Multiple Sclerosis, F2-Isoprostanes, Oxidative Stress

References
[1] B. Uttara, A. V. Singh, P. Zamboni, and R. T. Mahajan, “Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Current Neuropharmacology, 2009; 7(1): 65–74
[2] R. Dutta and B. D. Trapp, “Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007;68 (22): S22–S31.
[3] H. S. Mickel, “Multiple sclerosis: a newhypothesis. Perspectives in Biology and Medicine. 1975; 18 (3): 363–374.
[4] H. T. Besler and S. Comoglu. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutritional Neuroscience. 2003; 6 (3):189–196.
[5] J. A. Black, J. Newcombe, B. D. Trapp, and S. G. Waxman, Sodium channel expression within chronic multiple sclerosis Plaques. Journal of Neuropathology and Experimental Neurology. 2007; 66 (9): 828–837.
[6] B. D. Trapp, and S. G. Waxman, Sodium channel expression within chronic multiple sclerosis Plaques. Journal of Neuropathology and Experimental Neurology. 2007; 66 (9): 828–837.
[7] A. Ames III. Central nervous system energy metabolism as related to function. Brain Research Reviews. 2000; 34 (1-2): 42–68.
[8] H. Andrews, K. White, C. Thomson et al. Increased axonal mitochondrial activity as an adaptation to myelin deficiency in the shiverer mouse. Journal of Neuroscience Research. 2006; 83 (8): 1533–1539.
[9] E. Karg, P. Kliv´enyi, I. N´emeth, K. Bencsik, S. Pint´er, and L. V´ecsei. Nonenzymatic antioxidants of blood in multiple sclerosis. Journal of Neurology. 1999; 246 (7):533–539.
[10] GL. Milne, Q. Dai, LJ. Roberts LJ 2nd. The isoprostanes-25 years later. Biochim Biophys Acta. 2015; 1851(4):433-445.
[11] R.Gold, C. Linington, H. Lassmann. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006 (Pt 8):1953-1971.
[12] K. O'Brien, D. Fitzgerald, A.Rostami, B.Gran. The TLR7 agonist, imiquimod, increases IFN-beta production and reduces the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;221(1-2):107-111
[13] GL. Milne, H. Yin, JD. Brooks, S. Sanchez, L. Jackson Roberts 2nd, JD. Morrow JD. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol. 2007;433:113-126.
[14] DH. Mahad, BD. Trapp, H. Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183-193
[15] A. Langer-Gould, L. Qian, SY. Tartof, SM. Brara, SJ. Jacobsen, BE. Beaber, LS. Sy, C. Chao, R. Hechter, HF. Tseng. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014; 71(12):1506-1513
[16] D. Ontaneda, RJ. Fox, J. Chataway. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015; 14(2):208-223.
[17] VK. Harris, SA. Sadiq. Biomarkers of therapeutic response in multiple sclerosis: current status. Mol Diagn Ther. 2014; 18(6):605-617.
[18] G.G. Ortiz, F. P. Pacheco-Moisés, O. K. Bitzer-Quintero, A. C. Ramírez-Anguiano, L. J. Flores-Alvarado, V. Ramírez -Ramírez, M. A. Macias-Islas, E. D. Torres-Sánchez. Immunology and Oxidative Stress in Multiple Sclerosis. Clinical and Basic Approach. Neuroscience Letters. 2007; 414(3):233-236.
[19] P. Torricelli, P. Ferorelli, A. De Martino, F. Antonelli, A. Shevchenko, S. Beninati. Regression of Carotid Plaques in Individuals at Low-to-intermediate Cardiovascular Risk Treated with Citozym and Propulzym. European Journal of Preventive Medicine. 2014; 2 (3): 33-37.
[20] P. Torricelli, P. Ferorelli, A. De Martino, F. Antonelli, S.Beninati. Preventive Effects of A Mixture of Micronutrients with antioxidative Properties on Experimentally Induced Prostate Hyperplasia. American J Life Sci. 2013; 1(1): 22-26.
[21] P. Torricelli, F. Antonelli , P. Ferorelli , A. De Martino , A. Shevchenko , S. Beninati. Antiproliferative Activity of a Dietary supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines. Cancer Research Journal. 2014; 2 (2), 2014:29-32.
Author Information
  • Department SPES, University of Molise, Campobasso, Italy

  • University of Tor Vergata, Department of Biology, Rome, Italy

  • University of Tor Vergata, Department of Biology, Rome, Italy

  • University of Tor Vergata, Department of Biology, Rome, Italy

  • People’s Friendship University of Russia, Department of medicine, Moscow, Russia

  • University of Tor Vergata, Department of Biology, Rome, Italy

Cite This Article
  • APA Style

    Torricelli Piera, Antonelli Francesco, Ferorelli Pasquale, De Martino Angelo, Shevchenko Anna, et al. (2015). Multiple Sclerosis: Effect of Oral Administration of an Antioxidant Dietary Supplement in C57BL6/N Induced Model of Experimental Autoimmune Encephalomyelitis. American Journal of Clinical and Experimental Medicine, 3(3), 83-87. https://doi.org/10.11648/j.ajcem.20150303.12

    Copy | Download

    ACS Style

    Torricelli Piera; Antonelli Francesco; Ferorelli Pasquale; De Martino Angelo; Shevchenko Anna, et al. Multiple Sclerosis: Effect of Oral Administration of an Antioxidant Dietary Supplement in C57BL6/N Induced Model of Experimental Autoimmune Encephalomyelitis. Am. J. Clin. Exp. Med. 2015, 3(3), 83-87. doi: 10.11648/j.ajcem.20150303.12

    Copy | Download

    AMA Style

    Torricelli Piera, Antonelli Francesco, Ferorelli Pasquale, De Martino Angelo, Shevchenko Anna, et al. Multiple Sclerosis: Effect of Oral Administration of an Antioxidant Dietary Supplement in C57BL6/N Induced Model of Experimental Autoimmune Encephalomyelitis. Am J Clin Exp Med. 2015;3(3):83-87. doi: 10.11648/j.ajcem.20150303.12

    Copy | Download

  • @article{10.11648/j.ajcem.20150303.12,
      author = {Torricelli Piera and Antonelli Francesco and Ferorelli Pasquale and De Martino Angelo and Shevchenko Anna and Beninati Simone},
      title = {Multiple Sclerosis: Effect of Oral Administration of an Antioxidant Dietary Supplement in C57BL6/N Induced Model of Experimental Autoimmune Encephalomyelitis},
      journal = {American Journal of Clinical and Experimental Medicine},
      volume = {3},
      number = {3},
      pages = {83-87},
      doi = {10.11648/j.ajcem.20150303.12},
      url = {https://doi.org/10.11648/j.ajcem.20150303.12},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ajcem.20150303.12},
      abstract = {In the pathogenesis of demyelinating diseases including multiple sclerosis (MS) an important role is played by oxidative stress. Increased energy requirements during remyelination of axons and mitochondria failure is one of the causes of axonal degeneration and disability in MS. In the presence of neurological diseases such as MS, F2-isoprostanes are concentrated in higher quantities. In this context, we analyzed the levels of F2-isoprostanes in the plasma and cerebrospinal fluid of mice of the strain C57BL6/N with an induced experimental autoimmune encephalomyelitis (EAE), orally treated with two concentrations of Citozym, a dietary supplement with evident antioxidant properties. Compared to the control group, Citozym-treated EAE-mouse had significantly lower levels of F2-isoprostanes both in plasma and in cerebrospinal fluid. Furthermore, according to the guidelines of IACUC, treatment with Citozym at higher concentrations drastically reduced neurological signs of induced EAE.},
     year = {2015}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Multiple Sclerosis: Effect of Oral Administration of an Antioxidant Dietary Supplement in C57BL6/N Induced Model of Experimental Autoimmune Encephalomyelitis
    AU  - Torricelli Piera
    AU  - Antonelli Francesco
    AU  - Ferorelli Pasquale
    AU  - De Martino Angelo
    AU  - Shevchenko Anna
    AU  - Beninati Simone
    Y1  - 2015/04/18
    PY  - 2015
    N1  - https://doi.org/10.11648/j.ajcem.20150303.12
    DO  - 10.11648/j.ajcem.20150303.12
    T2  - American Journal of Clinical and Experimental Medicine
    JF  - American Journal of Clinical and Experimental Medicine
    JO  - American Journal of Clinical and Experimental Medicine
    SP  - 83
    EP  - 87
    PB  - Science Publishing Group
    SN  - 2330-8133
    UR  - https://doi.org/10.11648/j.ajcem.20150303.12
    AB  - In the pathogenesis of demyelinating diseases including multiple sclerosis (MS) an important role is played by oxidative stress. Increased energy requirements during remyelination of axons and mitochondria failure is one of the causes of axonal degeneration and disability in MS. In the presence of neurological diseases such as MS, F2-isoprostanes are concentrated in higher quantities. In this context, we analyzed the levels of F2-isoprostanes in the plasma and cerebrospinal fluid of mice of the strain C57BL6/N with an induced experimental autoimmune encephalomyelitis (EAE), orally treated with two concentrations of Citozym, a dietary supplement with evident antioxidant properties. Compared to the control group, Citozym-treated EAE-mouse had significantly lower levels of F2-isoprostanes both in plasma and in cerebrospinal fluid. Furthermore, according to the guidelines of IACUC, treatment with Citozym at higher concentrations drastically reduced neurological signs of induced EAE.
    VL  - 3
    IS  - 3
    ER  - 

    Copy | Download

  • Sections